Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) PT at $35.71

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have earned an average recommendation of “Buy” from the nine ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $35.71.

DAWN has been the subject of a number of research reports. Bank of America lowered their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. The Goldman Sachs Group lowered their price target on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, February 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st.

Insider Activity

In related news, insider Samuel C. Blackman sold 30,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total value of $399,300.00. Following the completion of the transaction, the insider now owns 1,034,015 shares of the company’s stock, valued at approximately $13,762,739.65. This represents a 2.82 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of large investors have recently bought and sold shares of DAWN. Handelsbanken Fonder AB raised its holdings in Day One Biopharmaceuticals by 16.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company’s stock worth $376,000 after purchasing an additional 3,900 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Day One Biopharmaceuticals by 38.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after purchasing an additional 1,002 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Day One Biopharmaceuticals by 87.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,203 shares of the company’s stock worth $267,000 after purchasing an additional 8,935 shares during the period. SteelPeak Wealth LLC raised its holdings in Day One Biopharmaceuticals by 9.8% in the 3rd quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock worth $242,000 after purchasing an additional 1,550 shares during the period. Finally, TimesSquare Capital Management LLC increased its stake in Day One Biopharmaceuticals by 8.2% during the 3rd quarter. TimesSquare Capital Management LLC now owns 1,827,695 shares of the company’s stock worth $25,460,000 after buying an additional 139,160 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN opened at $12.26 on Tuesday. The stock has a 50-day moving average of $12.44 and a two-hundred day moving average of $13.51. Day One Biopharmaceuticals has a one year low of $11.13 and a one year high of $18.07. The stock has a market cap of $1.24 billion, a P/E ratio of -11.90 and a beta of -1.46.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.